Biosimilars closed to commercialization challenges against a multinational company

Published: 2015-07-29 14:04:36

Updated: 2015-07-29 14:04:36

Domestic biosimilar development companies, highly anticipated to acquire approvals soon, are underway to nullify patents and launch their products early.

In order to launch their products early, Samsung Bioepis and Celltrion have challenged to patents of Humira(adalimumab, Abbott) and Mabthera(rituximab, Roche), which are close to commercialization.

The Humira biosimilar of Samsung Bioepis h...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.